About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Sham LaserCap vs. LaserCap SD vs. LaserCap HD+ | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNANCT05365360

Sham LaserCap vs. LaserCap SD vs. LaserCap HD+

Androgenetic alopecia (AGA) is a prevalent disease, occurring in 80% of Caucasian men and 50% of Caucasian women by age 701. Treatments for AGA are limited, and presently the only FDA-approved medicat...

Lead sponsor: University of Arizona•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Patrick Jedlowski, MD

CONTACT

(520) 694-8888 [email protected]

Sponsors

Lead Sponsor

University of Arizona

Collaborators

Transdermal Cap, Inc.

Age

25 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•25 years and older
•Men and women with AGA, untreated or with 6-month washout of previous treatments
•Men: Norwood stage IIa - V
•Women: Ludwig I-1 - II-2, or frontal pattern
•All patients: Fitzpatrick skin types I to IV

Exclusion Criteria

•Men: Norwood stage Va, VI, VII
•Women: Ludwig stage III, advanced
•All patients: Fitzpatrick skin types V, VI
•Current use or within the past six month of other treatment for AGA, including topical and oral minoxidil, topical and oral finasteride and dutasteride
•Age 0-25 years

Related studies

RECRUITINGPhase 3

Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia

NCT07080931 · Androgenetic Alopecia

RECRUITINGEARLY Phase 1

Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia

NCT07012486 · Androgenetic Alopecia (AGA)

Active Not RecruitingPhase 2

Safety and Efficacy of VDPHL01 in Males and Females With AGA

NCT06527365 · Androgenetic Alopecia, AGA, and more

Active Not RecruitingPhase 2

A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.

NCT07011485 · Alopecia, Androgenetic, Baldness, and more

COMPLETEDPhase 2

Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

NCT07076706 · Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 7, 2024Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment50

Start dateJun 2022

Last updatedMay 7, 2024

Condition

Androgenetic Alopecia

Locations shown

Banner University Dermatology

Tucson, Arizona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 7, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions